Empowering drug discovery with big data and artificial intelligence Any data that requires support from technological and infrastructural investments in order to get meaningful…Ben.frew@excelra.comApril 15, 2022 Read More
Drug target dossier: target intelligence for data-driven drug discovery Drug discovery and development is a long, expensive and risky process. On average it takes…Ben.frew@excelra.comApril 14, 2022 Read More
Digitization and data science in drug discovery It is amply clear that digitization and utilization of data science is playing an important…Ben.frew@excelra.comApril 14, 2022 Read More
Data in healthcare: how far have we come? Big data analytics was used as early as in 1600s for predicting epidemics of bubonic…Ben.frew@excelra.comApril 14, 2022 Read More
Data-driven drug repurposing “Pharma is taking a more of a data-driven and strategic approach to Drug Repurposing,” says…Ben.frew@excelra.comApril 14, 2022 Read More
Data curation for model-based meta analysis (MBMA) – an integral part of MID3 Model informed drug discovery and development (MID3) is a paradigm of data analytics in drug development…Ben.frew@excelra.comApril 14, 2022 Read More
Biologics – the biotech drugs transforming medicine Biologics, also known as biological products, are any type of medicines derived from living organisms…Ben.frew@excelra.comMarch 15, 2022 Read More
Coronavirus clinical trials landscape – analysis using Excelra’s COVID-19 biomarker database The ongoing COVID-19 pandemic is continuing to spread rapidly across the globe. As of 30th…Ben.frew@excelra.comMarch 15, 2022 Read More
Life Sciences Tech Trends 2021 COVID-19 has had an unprecedented adverse impact on global health and economy at large. While…Ben.frew@excelra.comApril 16, 2021 Read More
Pivotal role of biomarkers in diagnosing the ever changing landscape of COVID-19 infection The coronavirus (COVID-19) pandemic has proven to be a formidable scientific, medical, and social challenge.…Ben.frew@excelra.comDecember 16, 2020 Read More